The studies on CYP2D6 polymorphisms and their influences on tamoxifen efficacy show many discrepancies, which can be accounted to multiple factors, including variations in study design, in the definitions of breast cancer disease, and in the population characteristics. The gene discussed is CYP2D6; the disease is breast cancer.